Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

390602 Hydroxyfasudil - CAS 155558-32-0 - Calbiochem

A cell-permeable, hydroxylated metabolite of HA 1077 that displays anti-anginal properties.

MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

同义词: ROCK Inhibitor XIV, 1-(1-Hydroxy-5-isoquinolinesulfonyl)homopiperazine, HCl, HA1100

Primary Target: Rho-kinase
390602
Purchase on Sigma-Aldrich

概述

Replacement Information

重要规格表

CAS #Empirical Formula
155558-32-0C₁₄H₁₇N₃O₃S • HCl

Products

产品目录编号包装 数量 / 包装
390602-2MGCN 塑胶安瓿;塑胶针药瓶 2 mg
Description
OverviewA cell-permeable, hydroxylated metabolite of HA 1077 (Fasudil; Cat. No. 371970) that displays anti-anginal properties. Acts as an ATP-competitive and a reversible inhibitor of Rho-kinase (IC50 = 0.9 and 1.8 µM using a peptide and MLC as substrate, respectively) with ~100-fold greater selectivity over MLCK, MRCKβ, and PKC. Reported to inhibit the Rho kinase-mediated contraction both in vitro and in vivo.
Catalogue Number390602
Brand Family Calbiochem®
SynonymsROCK Inhibitor XIV, 1-(1-Hydroxy-5-isoquinolinesulfonyl)homopiperazine, HCl, HA1100
References
ReferencesIto, K., et al. 2003. J. Physiol. 546, 823.
Takemoto, M., et al. 2002. Circulation 106, 57.
Shimokawa, H., et al. 1999. Cardiovasc. Res. 43, 1029.
Product Information
CAS number155558-32-0
ATP CompetitiveY
FormLiquid
FormulationA 10 mM (2 mg/582 µl) solution in H₂O.
Hill FormulaC₁₄H₁₇N₃O₃S • HCl
Chemical formulaC₁₄H₁₇N₃O₃S • HCl
ReversibleY
Structure formula ImageStructure formula Image
Quality LevelMQ100
Applications
Biological Information
Primary TargetRho-kinase
Primary Target IC<sub>50</sub>0.9 and 1.8 µM against Rho-kinase using a peptide and MLC as substrate, respectively
Purity≥98% by HPLC
Physicochemical Information
Cell permeableY
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Blue Ice Only
Toxicity Harmful
Storage -20°C
Protect from Light Protect from light
Do not freeze Ok to freeze
Special InstructionsFollowing initial thaw, aliquot and freeze (-20°C).
Packaging Information
Packaged under inert gas Packaged under inert gas
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
产品目录编号 GTIN
390602-2MGCN 04055977189995

Documentation

Hydroxyfasudil - CAS 155558-32-0 - Calbiochem MSDS

职位

物料安全数据表 (MSDS) 

Hydroxyfasudil - CAS 155558-32-0 - Calbiochem 分析证书

标题批号
390602

参考

参考信息概述
Ito, K., et al. 2003. J. Physiol. 546, 823.
Takemoto, M., et al. 2002. Circulation 106, 57.
Shimokawa, H., et al. 1999. Cardiovasc. Res. 43, 1029.
数据表

Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

Revision12-March-2008 JSW
SynonymsROCK Inhibitor XIV, 1-(1-Hydroxy-5-isoquinolinesulfonyl)homopiperazine, HCl, HA1100
DescriptionA cell-permeable, hydroxylated metabolite of HA 1077 (Fasudil; Cat. No. 371970) that displays anti-anginal properties. Acts as an ATP-competitive and a reversible inhibitor of Rho-kinase (IC50 = 0.9 and 1.8 µM using a peptide and MLC as substrate, respectively) with ~100-fold greater selectivity over MLCK, MRCKβ, and PKC. Reported to inhibit the Rho kinase-mediated contraction both in vitro and in vivo.
FormLiquid
FormulationA 10 mM (2 mg/582 µl) solution in H₂O.
Intert gas (Yes/No) Packaged under inert gas
CAS number155558-32-0
Chemical formulaC₁₄H₁₇N₃O₃S • HCl
Structure formulaStructure formula
Purity≥98% by HPLC
Storage Protect from light
-20°C
Do Not Freeze Ok to freeze
Special InstructionsFollowing initial thaw, aliquot and freeze (-20°C).
Toxicity Harmful
ReferencesIto, K., et al. 2003. J. Physiol. 546, 823.
Takemoto, M., et al. 2002. Circulation 106, 57.
Shimokawa, H., et al. 1999. Cardiovasc. Res. 43, 1029.